Scientific Sessions 2026 Daily News: Monday, Nov. 9

See STROKE, page 4 American Heart Association Volunteer President Manesh Patel, MD, FAHA, delivered a bold challenge during Sunday’s Lewis A. Conner Lecture: Solve healthcare’s “last-mile problem” by ensuring proven medical discoveries reach patients in a timely and more equitable manner. The Duke University School of Medicine professor highlighted a stubborn gap between scientific breakthroughs and real-world patient care. He called it “science’s last-mile problem,” and argued that too many patients continue to miss out on therapies that can prevent heart attacks, strokes and other cardiovascular events. “Too many times in my career, I have met people for the first time on the cath lab table, while they are having a heart attack … And I see that they have not been treated with therapies we know could’ve helped prevent their disease,” said Patel, who also serves as chief of the division of cardiology and vice president of heart and vascular services for Duke Health in Durham, North Carolina. By example, Patel pointed to direct oral anticoagulants, noting that it took more than 14 years for these evidence-based therapies to become more widely prescribed than warfarin, despite research demonstrating their benefits years earlier. Barriers to quality cardiovascular care remain a global issue, he said, due to cost, limited healthcare access and poor adherence to treatment. Patel stressed that improving implementation science may be just as important as developing new treatments. “In my home state of North Carolina, limb loss dramatically varies across neighboring counties and regions — evidence that a person’s Zip code can have a greater impact than their genetic code,” he said. “Even more concerning and frustrating is the fact we can show similar maps for heart attacks and many other cardiovascular conditions. And it’s not just the United States.” Perhaps his strongest message was that of artificial intelligence’s impact on future cardiovascular care. He described AI as one of the most promising tools available to improve medical discovery and delivery of care, while emphasizing the importance of rigorous scientific guardrails. Patel noted the ADVOCATE program, an initiative supported by the Advanced Research Projects Agency for Health. It is designed to create FDA-authorized AI systems that can act as trusted digital members of clinical care teams. The envisioned AI “agents,” he said, could help patients access medications, schedule appointments, coordinate care and support personalized health management. “AI could and should reduce the friction patients face in getting care, and we face in delivering care,” he said, but cautioned, “If we’re not careful — if we don’t get this right in this early stage — these tools can also potentially widen the gaps that we’re seeking to close.” Patel: Solving science’s ‘last-mile problem’ OCEANIC-STROKE showed asundexian lowered ischemic stroke regardless of Framingham Risk Score category An exploratory post-hoc analysis of the OCEANIC-STROKE trial of oral asundexian vs. placebo for secondary stroke prevention showed the first-in-class Factor XIa (FXIa) inhibitor had similar efficacy and safety regardless of patients’ baseline Framingham Risk Score (FRS) category. The primary analysis, presented at the International Stroke Conference earlier this year, reduced the risk of recurrent ischemic stroke by 26% compared to placebo among patients with recent noncardioembolic ischemic stroke or high-risk transient ischemic attack. Efficacy was consistent across index stroke subtypes, including large artery atherosclerosis, small vessel occlusion or undetermined stroke. There was no interaction between asundexian efficacy or safety and FRS category. Patients at high risk by FRS were more likely to be older, male, have large artery atherosclerosis and be slated for dual antiplatelet therapy and less likely to be Asian than low- or medium-risk patients. But there was no statistically significant interaction between treatment effect and FRS category for ischemic stroke; a composite of cardiovascular death, myocardial infarction, stroke; major bleeding or clinically relevant nonmajor bleeding; minor bleeding; and net clinical benefit outcomes. This post-hoc analysis of the trial included a total of 12,264 patients with complete FRS data. “Asundexian worked as well for high-risk patients as it did for low-risk patients,” said Mukul Sharma, MD, Michael G. DeGroote Chair in Stroke Prevention and professor of neurology at McMaster University and senior scientist at the Population Health Research Institute in Hamilton, Canada. “We looked as well at net clinical benefit outcomes and again, no interaction.” The one caveat, he noted, was relatively small numbers of individuals in the low-risk category. The small numbers in the low-risk group led to wider confidence intervals than in the intermediate- and high-risk groups, but no significant interaction between treatment and FRS category was clear across all three risk groups for all efficacy and safety outcomes. Mukul Sharma, MD “This essentially coincides with what we found in the initial analysis, that asundexian worked well, and a second analysis where we saw Results from three Late-Breaking Science trials were presented during Saturday’s Main Event. Research found: • OCEANIC-STROKE showed Factor XIa inhibitor, asundexian, benefit for secondary stroke prevention across all nonlaboratory Framingham Risk Score categories among patients with noncardioembolic stroke or high-risk transient ischemic attack. • REDUCE found spironolactone-based treatment lowered home systolic blood pressure after stroke by nearly 8 mmHg more than standard care. • OPTIMAL-STROKE confirmed systolic blood pressure <120 mmHg improved secondary stroke prevention. Reports find multiple approaches improve outcomes after stroke Daily News #ScientificSessions26 Manesh Patel, MD, FAHA Monday Nov. 9, 2026

2 SCIENTIFIC SESSIONS DAILY NEWS | Monday, Nov. 9, 2026 Obesity Summit OBES.01 | Obesity Module 1: Overview and Understanding Obesity/Complexity and Origins of Obesity 9:30–9:50 a.m. | S105D OBES.02 | Obesity Module 2: How to Approach the Weight Discussion/Minimizing Bias 9:50–10:10 a.m. | S105D Obesity Module 3: Supporting Lifestyle Changes 10:10–10:30 a.m. | S105D OBES.04 | Obesity Module 4: Obesity Medicine/Pharmacologic Therapies 10:30–10:50 a.m. | S105D OBES.05 | Obesity Module 5: Surgical Procedures, Access to Care, Resources 10:50–11 a.m. | S105D OBES.06 | Obesity Module 6: Weight Loss Maintenance and Panel 11–11:30 a.m. | S105D Today at Sessions All sessions are located at the McCormick Place Convention Center unless otherwise noted. Late-Breaking Science and Featured Sessions LBS.05 | Late-Breaking Science: New Frontiers in Cardiometabolic Risk Reduction 8–9:15 a.m. | Center Stage, North Hall, Level 3 LBS.ID.03 | LBS In-Depth 3 8-9:15 a.m. | S103D FS.11 | Silencing ATTR-CM: Lessons From Helios-B and CardioTransform* 9:30–10:45 a.m. | Learning Studio 2, Science & Technology Hall JRNL.10 | GLP1 and Implications for Cardiometabolic and Cardiopulmonary Medicine: Henning Lecture 2026 9:45–11 a.m. | S102A LBS.06 | Late-Breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease 9:45–11 a.m. | Center Stage, North Hall, Level 3 FS.12 | Featured Science Potpourri* 1:30–2:45 p.m. | Heart Theater 2, Science & Technology Hall, Heart Hub FS.13 | Practice Informing RCTs* 1:30–2:45 p.m. | Learning Studio 2, Science & Technology Hall View the Industry Programming Guide for today’s events. Congenital Heart Disease Day Supported by Mussallem CHD Alliance CP.CVS.23 | Driving Progress in CHD: Where Research, Innovation and Clinical Care Meets Advocacy and Policy 8–9:15 a.m. | S100A CP.CVS.24 | Advances in Digital and Device-Based Monitoring for Children With CHD 9:45–11 a.m. | S100A CP.CVS.25 | The Journey Beyond Survival: What Matters Most to People Living With Congenital Heart Disease 11:15–11:45 a.m. | S100A CP.CVS.26 | “Is This the Moment?” Investment Panel Noon–1 p.m. | S100A Advancing Care in HFmrEF/HFpEF: Optimizing Therapies for Better Outcomes Request a Presentation Today! spotlight.heart.org Heart Failure affects approximately 6.7 million Americans age 20 and older and the need for effective care management continues to grow. Empower your team to enhance care for patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). LEARNING OBJECTIVES This program is sponsored by Bayer PAID ADVERTISEMENT © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1903575 9/26 • Early Treatment Initiation • Treatment Differentiation • HFmrEF/HFpEF Disease Burden • Reducing Residual Risk FREE GRAND ROUNDS EDUCATION IN PERSON OR VIRTUALLY

3 #ScientificSessions26 ScientificSessions.org Late-breaking trials challenge conventional treatments to cardiovascular disease Starting with a statin alone or with statin-ezetimibe led to similar outcomes when LDL-C goals were actively pursued In secondary prevention, whether to initiate statin monotherapy or combination therapy is an everyday decision clinicians face. Rather than the initial regimen itself, what matters most is actively adjusting lipid-lowering therapy in a targetdirected manner to achieve the LDL-C goal, according to “StatinEzetimibe Combination Therapy vs. Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Prespecified Second Randomization of the Ez-PAVE Trial.” The primary Ez-PAVE multicenter open-label trial randomized 3,048 adults with ASCVD 1:1 to an intensive LDL-C target of <55 mg/ dL or a conventional LDL-C target <70 mg/dL and found that targeting an LDL cholesterol level of <55 mg/ dL resulted in a reduced risk of cardiovascular events at three years. A prespecified second randomization simultaneously compared statinezetimibe combination therapy (1,525 patients) with statin monotherapy (1,523 patients) as an initial lipid-lowering strategy in both LDL-C target groups. In the statin-ezetimibe combination and monotherapy groups, the statin dose was determined according to each patient’s baseline LDL-C level and assigned LDL-C target. In the combination therapy group, patients received a fixed-dose combination of rosuvastatin and ezetimibe 10 mg. During follow-up, lipid-lowering therapy was adjusted according to a predefined protocol to achieve the assigned LDL-C target. In the statin monotherapy group, ezetimibe was added during follow-up in 34.3% of patients in the intensive-targeting group and 24.8% of patients in the conventional-targeting group. The statin-ezetimibe combination therapy produced greater LDL-C lowering than statin monotherapy, and a higher proportion of patients in the combination group reached lower LDL-C levels. However, the rate of the primary outcome, a composite of major cardiovascular events at three years, did not differ significantly between the statin-ezetimibe combination therapy and statin monotherapy groups. The primary outcome occurred in 8.5% of patients in the statin-ezetimibe combination group and 7.9% of patients in the statin monotherapy group. Byeong-Keuk Kim, MD, PhD “The findings suggest that when LDL-C targets are actively pursued and therapy is adjusted accordingly, clinical outcomes are similar whether treatment begins with combination therapy or with a statin alone,” said co-investigator ByeongKeuk Kim, MD, PhD, professor of cardiology at Yonsei University College of Medicine and director of the Cardiovascular Intervention Room at Severance Cardiovascular Hospital in Seoul, South Korea. “When LDL-C levels are monitored and therapy is adjusted to reach the treatment goal, starting with statin monotherapy and adding ezetimibe as needed appears to be a reasonable strategy, with clinical outcomes comparable to those of upfront combination therapy.” Kim noted that the study’s findings support the goal-directed approach emphasized in the “2026 ACC/AHA/AACVPR/ABC/ ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA Guideline on the Management of Dyslipidemia,” which reintroduced LDL-C goals for patients with ASCVD and recommends adding ezetimibe when maximally tolerated statin therapy doesn’t achieve these goals. The study was published in Circulation following the presentation. Discontinuation of statin therapy for primary prevention was noninferior to continuation with respect to major cardiovascular events or death from any cause at two years Physicians are already recommending deprescription, with 80% of general practitioners from 30 countries advising discontinuation of statin therapy in persons at least 80 years of age without cardiovascular disease who have statin-related side effects or frailty. But is it safe? That was the question asked in “Discontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Noninferiority Clinical Trial (STREAM).” The multicenter noninferiority trial conducted in 24 centers in Switzerland, France and the Netherlands, randomly assigned 1,880 adults ≥70 years with at least two comorbidities without cardiovascular disease 1:1 to either discontinue statin use (intervention arm) or continue statin use (control arm). The primary endpoint compared the primary composite endpoint of major cardiovascular events (nonfatal myocardial infarction or nonfatal ischemic stroke) and all-cause death between the control and intervention groups over a follow-up of up to 48 months. Results showed that among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuation of statin therapy was noninferior to continuation with respect to major cardiovascular events or death from any cause over two years. During the first two years of follow-up, 100 participants (10.7%) in the discontinuation group and 77 (8.2%) in the continuation group had a primaryoutcome event. Over the full followup period (median, 103 weeks), 119 participants (12.7%) in the discontinuation group and 87 (9.2%) in the continuation group had a primary-outcome event. Nicolas Rodondi, MD, MAS “Our findings provide information for shared decisionmaking about cautious statin discontinuation when statins are used for primary prevention only. Although deprescribing inappropriate drugs in older adults appears to be safe, the results of our trial suggest that additional randomized trials of discontinuation are needed for specific drugs,” Trial results presented in Saturday’s Late-Breaking Science session shed light on new approaches to initiating lipid-lowering therapy in secondary prevention, statin discontinuation in older adults for primary prevention, intensive blood pressure control and cardiovascular risk in people with type 2 diabetes and a novel cardiac rehabilitation. Their results found: • Starting with statin-ezetimibe combination therapy lowered LDL-C more than starting with a statin alone, but cardiovascular outcomes were similar when therapy was adjusted to reach LDL-C goals in secondary prevention. • Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuation of statin therapy is noninferior to continuation with respect to major cardiovascular events or death from any cause at two years. • Targeting a systolic blood pressure below 120 mmHg did not significantly reduce major cardiovascular events compared with a target below 140 mmHg in adults with type 2 diabetes in Brazil. • Yoga-based cardiac rehabilitation did not reduce mortality, hospitalization or stroke in patients with heart failure. See CARDIOVASCULAR, page 6

4 SCIENTIFIC SESSIONS DAILY NEWS | Monday, Nov. 9, 2026 good efficacy and safety across the various stroke subtypes,” Sharma said. “It’s not the case that one has to think very hard about what the patient’s risk is and what exactly the risk factors are before determining eligibility for asundexian. It seems to work well across a number of risk strata. The major clinical implication is that it is easy to use for a wide variety of patients.” Asundexian is the FXIa inhibitor to reach phase 3 trials. A second agent, milvexian, may report topline phase 3 results in early 2027. “This is the first agent in the class, and I expect it to have an effect on guidelines,” Sharma said. “If there are two trials, both of which show similar results, it becomes much easier for guideline writers to revisit secondary stroke prevention.” Asundexian is the first FXI/FXIa inhibitor to reach phase 3 trials. A second agent, milvexian, may report top line phase 3 results in early 2027. “This is the first agent in the class and I expect it to have an effect on guidelines,” Sharma said. “If there are 2 trials, both of which show similar results, it becomes much easier for guideline writers to revisit secondary stroke prevention.” Spironolactone-based treatment lowered post-stroke blood pressure nearly 8 mmHg vs. usual care Hypertension is the leading modifiable risk factor for recurrent stroke, yet post-stroke blood pressure control remains suboptimal. A randomized, open-label trial comparing spironolactone-containing blood pressure regimens following ischemic stroke or intracerebral hemorrhage (ICH) found clinically significant and durable reductions in home blood pressure compared to usual care. Initial results of the “Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke (REDUCE) Trial” showed a mean difference in home systolic blood pressure of 7.7 mmHg at three months and 6.9 mmHg at six months compared to standard care. “These were not patients with resistant hypertension; these were people who, at baseline, were on an average of two antihypertensive medications,” said Jordana Cohen, MD, MSCE, FAHA, associate professor of medicine and epidemiology at the University of Pennsylvania Perelman School of Medicine in Philadelphia “There is a lot to be said for the benefit of blocking aldosterone post-stroke. Historically, spironolactone is something we sometimes use as our fourth drug, but we may want to be thinking about it as a second or third drug post-stroke.” Jordana Cohen, MD, MSCE, FAHA REDUCE randomized 160 patients following ischemic stroke or ICH across five U.S. centers to either a spironolactone-based blood pressure regimen (85 patients) or standard care (75 patients), in which treating clinicians received a letter summarizing 2017 ACC/ AHA high blood pressure guideline recommendations for stroke survivors. The mean age of trial participants was 63 years; 37% were female and 29% Black; 54% had ICH and 46% had ischemic stroke. The mean baseline systolic blood pressure was 136 mmHg, and participants were taking a mean of two antihypertensive medications. The primary outcome was home systolic blood pressure (SBP) at three months. Secondary outcomes included home diastolic blood pressure (DBP) at three months, home SBP/DBP at six months, the number of concomitant antihypertensive medications at three months and the proportion achieving blood pressure target of <130/80 mmHg at three months. At three months, the spironolactone group had a mean SBP of 125.6 mmHg vs. 133.3 mmHg for standard care, a mean difference of -7.7 mmHg (95% CI: [-11.6, -3.8], p=0.0002). The difference was similar at six months: 124.0 vs. 130.9 mmHg, a mean difference of -6.9 (95% CI: [-10.6, -3.2], p=0.0004). Participants in the spironolactone group were taking more antihypertensive medications at 3 months, including spironolactone: 2.6 vs. 2.1, for a mean difference of 0.5 (95% CI: [0.2, 0.9], p=0.004). Serious adverse event rates were similar: 15% for spironolactone vs. 16% for standard care. Spironolactone showed higher rates of hypotension (8% vs. 1%), lightheadedness (5% vs. 1%) and hyperkalemia (4% vs. 0%) vs. STROKE continued from page 1 Delta Dental is proud to collaborate with the American Heart Association’s Healthy Smiles, Healthy Hearts Initiative. Delta Dental is a registered trademark of Delta Dental Plans Association. Expand Your Understanding of the Dynamic Connection Between Oral and Cardiovascular Health Access our vodcast series, eModule, and other resources bringing the latest science and evidence-based strategies for you to learn about topics like patient safety, accurate blood pressure measurement, and how oral health can be associated with increased risk for cardiovascular disease and stroke risk. Multiple CE credits available, including ADA CERP. American Heart Association. Unauthorized use prohibited. WF-1928217 10/26 LEARN NOW PAID ADVERTISEMENT

5 #ScientificSessions26 ScientificSessions.org usual care. The trial was not powered to assess recurrent stroke or other clinical events. Enrollment closed early at 160 of the planned 200 participants because of slow recruitment, and 15% of participants lacked the 3-month primary outcome; a multiple imputation analysis including all 160 participants showed a similar difference of -6.9 mmHg (95% CI: [-10.7, -3.0]). “Every way we looked at blood pressure, patients had about an 8 mmHg lowering of systolic blood pressure,” Cohen said. “And just over half of patients achieved a blood pressure goal of less than 130/80 mmHg in the spironolactone group, compared to 30% in the usual care group. We should be thinking about blocking aldosterone earlier in the treatment of hypertension after stroke.” Clinical benefits to systolic blood pressure <120 mmHg after ischemic stroke or TIA A randomized trial of blood pressure control in more than 4,000 ischemic stroke or transient ischemic attack survivors showed a 21% relative reduction in subsequent major cardiovascular events for systolic blood pressure <120 mmHg compared to standard care, which was defined as a systolic blood pressure target <140 mmHg. The median follow-up was 3.9 years. Gisele Sampaio Silva, MD, MPH, PhD “High blood pressure is the most important modifiable risk factor for stroke and controlling it is central to preventing a second stroke,” said Gisele Sampaio Silva, MD, MPH, PhD, head of Neurology Clinical Trials at Einstein Hospital Israelita in São Paulo, Brazil. “Yet one practical question has remained unanswered: After an ischemic stroke, how low should blood pressure go?” The OPTIMAL-STROKE trial directly compared two approaches to blood pressure control after ischemic stroke. The trial randomized 4,368 participants from 30 sites across Brazil to either intensive blood pressure control, systolic blood pressure <120 mmHg, or standard care, which the trial defined as systolic blood pressure <140 mmHg. All of the participants had a prior ischemic stroke or transient ischemic attack and high blood pressure with systolic blood pressure between 130 and 180 mmHg. At baseline, the mean blood pressure was 146.7/81.6 mmHg. The mean age of participants was 63.9 years, and 47.9% were female. Just over half (56.8%) self-identified as white, 29.8% as mixed race and 12.1% as Black. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina or hospitalization for heart failure. Secondary endpoints included the individual components of the primary outcome; a composite of cardiovascular mortality, nonfatal MI or nonfatal stroke; a composite of all-cause mortality, nonfatal MI or nonfatal stroke; hospitalization for unstable angina or heart failure; allcause mortality and renal outcomes. “Among patients with high blood pressure and previous ischemic stroke or transient ischemic attack, major cardiovascular events were significantly less frequent with intensive treatment targeting systolic blood pressure below 120 mmHg than with standard treatment targeting systolic blood pressure below 140 mmHg,” said Otavio Berwanger, MD, PhD, professor and executive director at The George Institute for Global Health and Imperial College London in the U.K. Berwanger chaired the OPTIMALSTROKE Trial Steering Committee. At 48 months, the median systolic blood pressure in the intensive treatment group was 119.9 mmHg vs. 135.2 mmHg in the standard treatment group. A primary outcome event occurred in 10.9% of the intensive control group (3.25 events per 100 personyears) compared with 13.5% of the standard treatment group (4.11 events per 100 person-years). The hazard ratio (HR) for intensive blood pressure control was 0.79 (95% CI: [0.67, 0.94], p=0.007). Event curves separated during the first few months of follow-up and continued to separate over time. Otavio Berwanger, MD, PhD Secondary outcomes generally favored intensive BP control. The HR for cardiovascular mortality, nonfatal See STROKE, page 7 You’ve explored the challenges. Now take the next step. As cardiovascular-kidney-metabolic (CKM) syndrome guidance evolves, so should implementation. Download the CKM Health Implementation Guide 2.0, updated to reflect the new 2026 CKM Syndrome Guideline, and bring evidence-based care into everyday clinical practice. What’s inside Implementation Guide 2.0? • Tools to evaluate and optimize care delivery • Evidence-based CKM syndrome education for care teams • Actionable implementation strategies and clinical examples • Patient resources to improve awareness and understanding • Quality improvement opportunities to enhance outcomes The American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative is made possible by Founding Sponsors Novo Nordisk and Boehringer Ingelheim, Supporting Sponsors Novartis Pharmaceuticals Corporation and Bayer, and Champion Sponsor DaVita. PAID ADVERTISEMENT © 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. 9/26 WF1772201 CARDIOVASCULARKIDNEY-METABOLIC HEALTH IMPLEMENTATION GUIDE For health care organizations and professionals working in primary care, nephrology, endocrinology, cardiology and beyond. DOWNLOAD YOUR GUIDE TODAY Heart.org/CKMtools The Journey Doesn’t Stop Here 2.0 WF-1772201 CKM Scientific Sessions Print Ads-_2026-5.indd 5 9/22/26 9:37 AM

6 SCIENTIFIC SESSIONS DAILY NEWS | Monday, Nov. 9, 2026 said Nicolas Rodondi, MD, MAS, professor of primary care and internal medicine and director of the Institute of Primary Health Care at the University of Bern, Switzerland. Rodondi estimated that one additional major cardiovascular event or death would occur over a period of two years for every 40 persons who discontinued statin therapy, which will require further investigation. In a secondary analysis of investigating patientcentered outcomes, including pain, quality of life, fall risk and muscle weakness, there was no difference between the two groups. After the presentation, the study was published in the New England Journal of Medicine. Intensive systolic blood pressure target did not reduce cardiovascular events in type 2 diabetes Lowering systolic blood pressure (SBP) <120 mmHg did not significantly reduce major cardiovascular events in people with type 2 diabetes compared with targeting SBP <140 mmHg, according to “Intensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes, the OPTIMALDIABETES Trial.” The open-label trial enrolled a diverse population of 9,476 men and women ≥50 years with type 2 diabetes, hypertension (mean SBP 130-189mmHg) and high cardiovascular risk at 33 centers across Brazil. Participants were randomized 1:1 to a SBP target <120 mmHg (intensive control group) or <140 mmHg (standard strategy), with active blood pressure adjustments to achieve assigned targets over a median of 48 months. The primary endpoint, a composite of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or hospitalization for heart failure, occurred in 286 people in the intensive group and 315 in the standard group. During follow-up, mean SBP was 13.7 mmHg lower in the intensive group. The difference in the primary endpoint between groups was not statistically significant (HR 0.90; 95% CI: [0.77, 1.06], p=0.20). Decline in kidney function was more common with intensive treatment. End-stage kidney disease was rare and occurred at similar rates in both groups. Otavio Berwanger, MD, PhD “OPTIMAL-DIABETES does not support routinely aiming for systolic blood pressure below 120 mmHg in this population, but that does not mean intensive blood pressure lowering is ineffective in diabetes,” said Otavio Berwanger, MD, PhD, executive director of the George Institute for Global Health and Imperial College London, UK, and chair of the OPTIMAL-DIABETES trial steering committee. “It suggests that any cardiovascular benefit is likely to be smaller than in people without diabetes, and too small for even a large single trial to detect with certainty.” Berwanger noted that OPTIMALDIABETES makes a substantial contribution to the overall evidence and highlights the need for a pooled analysis that combines individual patient data across trials, including ACCORD-BP and BPROAD, to determine whether some groups of people with diabetes benefit more than others from an intensive blood pressure lowering strategy. “Given how common type 2 diabetes is worldwide, even a modest reduction in cardiovascular risk could mean a large public health gain,” he said. The study was published in the New England Journal of Medicine after the presentation. Yoga-based cardiac rehabilitation improved quality of life but did not reduce death, hospitalization or stroke in patients with heart failure Yoga-based cardiac rehabilitation did not reduce the first co-primary outcome, a composite of all-cause mortality, all-cause hospitalization and stroke, but improved quality of life, six-minute walk distance (6MWD) and quality-adjusted utility values in patients with reduced ejection fraction (HFrEF), according to “A Randomized Trial of YogaBased Cardiac Rehabilitation in Heart Failure (Yoga-CaRe HF Trial).” The multicenter controlled trial randomized 3,492 patients in India with heart failure with reduced ejection fraction to receive a yogabased cardiac rehabilitation program delivered by a single trained yoga instructor (n=1737, intervention group) or enhanced standard care (n=1755, control group). Mean age CARDIOVASCULAR continued from page 3 Learn the latest on HFmrEF/HFpEF in the American Heart Association’s podcast series and eModule. • Diagnosis • Heart Failure Phenotypes • Connection to Cardio-Kidney-Metabolic Syndrome • Medical and Device Therapies • Practical Application and Access to Treatment Funding for this American Heart Association educational program is provided by Bayer. Learn Now HFmrEF/HFpEF: From Symptoms to Solutions © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1932190 9/26 PAID ADVERTISEMENT American Heart Association® Lifelong LearningTM

7 #ScientificSessions26 ScientificSessions.org was 57; 27% were female; almost 50% were in NYHA III. The co-primary outcomes were time to the first occurrence of a composite of all-cause mortality, allcause hospitalization and stroke, and quality of life was assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) at three months. Secondary confirmatory outcomes were 6MWD and qualityadjusted utility values based on the European Quality of Life Questionnaire (EQ-5D-5L). The first co-primary outcome occurred in 364 patients (21.0%) in the intervention group and 401 (22.8%) in the control group (HR=0.90; 95% CI: [0.78, 1.04], p=0.15). The second co-primary outcome, MLHFQ score, improved more with yoga-based rehabilitation (between-group difference in change from baseline -8.06; 95% CI: [-8.87, -7.24], p<0.001); lower scores indicate better quality of life. Similar improvements were observed in the secondary confirmatory outcome, 6MWD (between-group difference in change from baseline 25.5; 95% CI: [20.8, 30.3], p<0.001), and qualityadjusted utility values based on the EQ-5D-5L, with a between-group difference in change from baseline (0.05; 95% CI: [0.03, 0.06], p<0.001). Overall, although yoga-based rehabilitation did not significantly reduce all-cause mortality, all-cause hospitalization and stroke, it improved quality of life, increased 6MWD and quality-adjusted utility-value at three months, with the difference persisting through 24 months. Dorairaj Prabhakaran, MD “Reducing hospitalizations and improving quality of life with heart failure is much needed in countries like India, where an estimated 500,000 to 1.8 million new heart failure cases are diagnosed each year,” said principal investigator Dorairaj Prabhakaran, MD, executive director of the Center for Chronic Disease Control in New Delhi, India. He noted that future research needs to focus on scaling yoga interventions and evaluating their effectiveness across diverse international settings. MI or nonfatal stroke was 0.81 (95% CI: [0.68, 0.98], p=0.03), for allcause mortality, nonfatal MI/stroke or hospitalization for unstable angina/heart failure 0.84 (95% CI: [1.24, 0.97], p=0.02) and for stroke 0.73 (95% CI: [0.56, 0.94]). Other secondary cardiovascular outcomes were not statistically significant. The intensive blood pressure control group had worse renal outcomes, HR 1.76 (95% CI: [1.21, 2.50]). There were similar rates of serious adverse events, orthostatic hypotension, or injuries. Berwanger noted that the increase in kidney-related events, primarily reductions in kidney function, underlines the need for individualized treatment and careful monitoring for all patients. “Many clinicians have worried that lowering blood pressure too far after an ischemic stroke could reduce blood flow to the brain and trigger another event,” he said. “In clinically stable patients, we saw fewer ischemic strokes, not more, with a target below 120 mmHg. It is also meaningful that we showed this benefit in a population that has been underrepresented in previous trials of intensive blood pressure lowering.” OPTIMAL-STROKE was published simultaneously in the New England Journal of Medicine. STROKE continued from page 5 Be sure to visit the Poster Hall In the Science & Technology Hall Find out how Lp(a) impacts your patients Novartis Pharmaceuticals Corporation supports Driving Awareness and Shared Decision-Making Around Lp(a) 2026. © 2026 American Heart Association, Inc., 501(c)(3) not-for-profit. All rights reserved. Lifelong Learning is a trademark of the AHA. Unauthorized use prohibited. WF650001 10/26 Paid Advertisement Lp(a) Toolkit for Healthcare Professionals High levels of plasma lipoprotein(a) (Lp(a)) are independently associated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of myocardial infarction, peripheral arterial disease, and stroke. Learn more in this toolkit for healthcare professionals. Lp(a): A Survey for Healthcare Professionals We invite you to take part in a brief survey designed to assess your knowledge of Lp(a) and help us understand your practice. Your responses will help the American Heart Association shape future educational activities that drive further awareness of Lp(a) screening and overall ASCVD risk management.

The American Heart Association is grateful for the continued support and generosity of our exhibitors and sponsors. We want to recognize the following companies for their support of additional sponsorship and advertising opportunities. • Alnylam Pharmaceuticals, Inc. • Amgen Inc. • Ann & Robert Lurie Children’s Hospital of Chicago • Answers in CME • Arrowhead Pharmaceuticals, Inc. • AskBio Inc. • AstraZenca • Bayer • Boehringer Ingelheim Pharmaceuticals, Inc • BridgeBio Pharma, Inc. • Bristol Myers Squibb • Bristol Myers Squibb | Johnson & Johnson • Caristo Diagnostics • Cedar Sinai Hospital • Cleerly, Inc • Corcept Therapeutics Inc • Cytokinetics, Inc. • Decera Clinical • Edwards Lifesciences LLC • Eli Lilly & Company • Esperion Therapeutics, Inc. • Haymarket Medical Education • (Heart) Cardiovascular-KidneyMetabolic Syndrome (CKMH) • (Heart) Quality, Outcomes, Research & Analytics • (Heart) Target: Aortic Stenosis | Quality & Health IT • Heartflow, Inc. • Idorsia Pharmaceuticals USA • Intellia Therapeutics, Inc. • Ionis Pharmaceuticals Inc. • Kiniksa Pharmaceuticals Corporation • Lexeo Therapeutics, Inc. • LIB Therapeutics • Medscape Live Meeting Services • Medtronic, Inc. • Merck & Co., Inc. • Milestone Pharmaceuticals, Inc • Mineralys Therapeutics • New Amsterdam Pharma • Novartis Pharmaceutical Corporation • Novo Nordisk, Inc. • PeerView Operation Services America LLC • Pfizer Inc. • Prime Education • Vindico Medical Education • Wolters Kluwer Educational Grant Support Provided by: • AstraZeneca Pharmaceuticals • Alnylam U.S., Inc. • DexCom, Inc. • Novartis Pharmaceutical Corporation • Chiesi USA, Inc. • Biosence Webster, Inc. • Boston Scientific Corporation • Abbott Laboratories • J&J MedTech, Heart Recovery • Impulse Dynamics • Stryker Corporation Thank You Watch your favorite presenters anytime, anywhere Take Scientific Sessions With You LEARN MORE

RkJQdWJsaXNoZXIy MjI2NjI=